Codexis, Inc. CDXS
We take great care to ensure that the data presented and summarized in this overview for CODEXIS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDXS
View all-
Opaleye Management Inc. Boston, MA12.8MShares$21.1 Million5.2% of portfolio
-
Black Rock Inc. New York, NY6.79MShares$11.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.67MShares$7.71 Million0.0% of portfolio
-
Abrdn PLC4.09MShares$6.75 Million0.02% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.07MShares$6.71 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.03MShares$6.65 Million0.4% of portfolio
-
Telemark Asset Management, LLC Boston, MA4MShares$6.6 Million0.99% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN2.77MShares$4.58 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.99MShares$3.29 Million0.0% of portfolio
-
Pier Capital, LLC Stamford, CT1.89MShares$3.12 Million0.79% of portfolio
Latest Institutional Activity in CDXS
Top Purchases
Top Sells
About CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Insider Transactions at CDXS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
253,533
-3.46%
|
$253,533
$1.67 P/Share
|
|
Nov 28
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
107,490
-1.16%
|
$107,490
$1.75 P/Share
|
|
Nov 26
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,000
-2.55%
|
$5,000
$1.74 P/Share
|
|
Nov 26
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private sale
|
Indirect |
148,318
+1.42%
|
$148,318
$1.74 P/Share
|
|
Nov 21
2025
|
Dennis P Wolf |
SELL
Open market or private sale
|
Direct |
8,952
-6.05%
|
$8,952
$1.56 P/Share
|
|
Nov 13
2025
|
Alison Moore President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+25.05%
|
-
|
|
Nov 12
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
192,459
-6.92%
|
$192,459
$1.95 P/Share
|
|
Nov 12
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private sale
|
Indirect |
890,000
+7.73%
|
$890,000
$1.94 P/Share
|
|
Nov 11
2025
|
Raymond De Vre |
SELL
Open market or private sale
|
Direct |
1,413
-1.59%
|
$1,413
$1.74 P/Share
|
|
Nov 11
2025
|
Stephen George Dilly |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+6.43%
|
$50,000
$1.85 P/Share
|
|
Nov 11
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
548,211
-5.01%
|
$548,211
$1.8 P/Share
|
|
Nov 10
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
208,318
-1.53%
|
$208,318
$1.73 P/Share
|
|
Nov 07
2025
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-4.0%
|
$10,000
$1.7 P/Share
|
|
Nov 07
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private sale
|
Indirect |
296,682
+2.36%
|
$296,682
$1.7 P/Share
|
|
Oct 13
2025
|
Georgia Erbez Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,239
-8.12%
|
$12,478
$2.5 P/Share
|
|
Oct 13
2025
|
Alison Moore President and CEO |
SELL
Open market or private sale
|
Direct |
6,239
-3.55%
|
$12,478
$2.51 P/Share
|
|
Aug 04
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
780
+0.01%
|
$1,560
$2.84 P/Share
|
|
Jul 31
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
84,220
+0.67%
|
$168,440
$2.68 P/Share
|
|
Jul 30
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,578
+0.01%
|
$3,156
$2.8 P/Share
|
|
Jul 29
2025
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,422
+0.07%
|
$16,844
$2.82 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 3.99M shares |
|---|---|
| Open market or private sale | 1.34M shares |
| Grant, award, or other acquisition | 748K shares |
| Open market or private sale | 1.35M shares |
|---|